 |
|
|
|
  |
|
* IMS DDD Lung Surfactant Market Purchases July 1991 through June 2007. On file, Abbott Nutrition Marketing Research.
SURVANTA CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. During controlled clinical trials, the most commonly reported adverse experiences were associated with the dosing procedure: Transient bradycardia 11.9% of doses; oxygen desaturation 9.8% of doses; ETT reflux, fewer than 1% of doses.
|
|
|
|
